Share this article Share this article SAN CARLOS, Calif., Feb. 3, 2021 /PRNewswire/ -- IncellDx, a leading precision medicine diagnostics company, has filed patents for algorithms identifying immunologic profiles unique to COVID long haulers and patients with severe COVID. IncellDx has developed and patented two distinct algorithms using machine learning, built on a tailored panel of cytokines and chemokines specific for abnormalities in cytokine storm conditions and in chronic COVID patients (often referred to as COVID "long haulers"). These have been submitted for publication (pre-print available through BioRx https://www.biorxiv.org/content/10.1101/2020.12.16.423122v1). The first algorithm generates a severity score based on analysis of hundreds of COVID-19 patients spanning the spectrum of disease severity from mild to critical. The second algorithm derived from the same cytokine/chemokine immune panel, demonstrates that the immunology of long haulers is distinct from active COVID-19. This objective algorithm offers the opportunity for precision medicine to be used by physicians as a guide in the care of COVID-19 patients.